ArticleAmerican journal of translational research2015

The advantages of PD1 activating chimeric receptor (PD1-ACR) engineered lymphocytes for PDL1(+) cancer therapy.

Xiaolong Tang et al.PubMed ↗Full text ↗

No numbers read from the abstract.